Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Faron Pharmaceuticals Oy LSE:FARN London Ordinary Share FI4000153309 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -12.50 -4.13% 290.00 280.00 300.00 297.50 290.00 297.50 18,349 09:21:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -11.2 -26.2 - 136

Faron Pharmaceuticals Oy Share Discussion Threads

Showing 1551 to 1572 of 1575 messages
Chat Pages: 63  62  61  60  59  58  57  56  55  54  53  52  Older
DateSubjectAuthorDiscuss
25/10/2020
15:23
FARN CONSENSUS BUY TGT 482P https://www.-/insights/
taffyeight
25/10/2020
13:29
Potential investors and current shareholders may be interested in our webinar with Faron Pharmaceuticals (FARN), 3 November 2020 hTTps://www.sharesoc.org/events/sharesoc-webinar-with-faron-pharmaceuticals-farn-3-november-2020/
sharesoc
25/10/2020
13:29
Potential investors and current shareholders may be interested in our webinar with Faron Pharmaceuticals (FARN), 3 November 2020 hTTps://www.sharesoc.org/events/sharesoc-webinar-with-faron-pharmaceuticals-farn-3-november-2020/
sharesoc
16/10/2020
14:41
“They do support our long-held view that IFN beta-1a is likely to be ineffective when given subcutaneously." It will be interesting to know whether use of Traumakine continued after the cut-off date for this analysis, or whether any useful information (for Faron) ever becomes available. A plus for the company is that their prediction (about subcutaneous efficacy) was vindicated.
hashertu
16/10/2020
12:52
Faron Pharmaceuticals Oy (LON:FARN) said it was disappointed by results from a study that showed little impact from interferon Beta-1a injected under the skin in halting coronavirus-related deaths. The World Health Organisation's (WHO) Solidarity trial compared 1412 patients who received IFN beta-1a and 2050 control subjects not receiving IFN beta-1a. The results show that subcutaneous interferon (IFN) beta-1a was found to be safe, but ineffective to reduce overall mortality in hospitalised patients with COVID-19. Faron’s IFN Beta-1a candidate Traumakine was part of the Solidarity trial, but the company said it only became available very late in the observation period and its understanding was that it had seldom been used. “The WHO has not been able to verify how many patients received Traumakine at the time of this analysis,” said Faron in a statement. About half of the patients receiving IFN beta-1a also received concomitant corticosteroids, which Faron believes hampered the effectiveness of Traumakine in a previous trial. Markku Jalkanen, Faron's CEO, said: "These first results from the Solidarity Trial are disappointing, given the need for new therapeutics to support the global response to COVID-19. “They do support our long-held view that IFN beta-1a is likely to be ineffective when given subcutaneously. “The science behind Traumakine and its potential to prevent multi-organ failure, through the upregulation of the key endothelial enzyme CD73, is compelling and we continue to believe that an intravenous formulation of IFN beta-1a is what patients need, to strengthen the body's own IFN beta signalling - the first line of defence against viral infection - and provide optimal exposure to the lung vasculature. "Compared to subcutaneous IFN beta-1a, the same amount of intravenous IFN beta-1a achieves over 150x higher peak concentration in the lung vasculature without higher systemic exposure, which we believe makes this method of administration highly effective and safe. “We will continue to pursue the science behind this." Shares in Faron dropped 21% to 347p.
latifs100
16/10/2020
09:59
This is Farn IV I think “ Solidarity’s “most disappointing results,” however, are those for interferon-beta, says Topol. Mortality among the 2050 people who received that drug (either alone or in combination with lopinavir/ritonavir) was 11.9%, versus 10.5% in the control group". htTps://www.sciencemag.org/news/2020/10/remdesivir-and-interferon-fall-flat-who-s-megastudy-covid-19-treatments
toffeeman
16/10/2020
09:48
Seing plenty different opinions...So does it actually work or not???
alexios1201
16/10/2020
08:58
Because IV doesn't work in Covid
toffeeman
16/10/2020
08:51
why the droptoday?
latifs100
28/9/2020
08:45
Interesting price action today - volume picking up a bit
raldo
25/9/2020
06:10
An interesting write up on Bloomberg about the "increasing evidence (that)suggests that some Covid-19 patients get very ill because of an impaired interferon response". with the likes of the NYT and now Bloomberg picking up on the various studies in journals such as Nature, this can only help to build awareness for the potential of IV-IFN treatments. https://www.bloomberg.com/news/articles/2020-09-24/covid-doctors-follow-dna-trail-to-potential-immune-treatment
jojaken
28/8/2020
07:10
hxxps://www.faron.com/news-events/events hxxps://hcwco.com/transactions/ https://www.yahoo.com/lifestyle/h-c-wainwright-co-once-203000629.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmZpLw&guce_referrer_sig=AQAAAEIArhKX8VK-eDmihWQp8_Oys64_eO-IIRBKb-KThf-jpcVew6rlucJoD-Zlw3dNYU6AorYBD2Djok4BLYMD6hB6FiFXm_Dg9pBN3GW15gkh1f3BqaMXi7cntc7cwp2dreI4gJpBR1HbZT2pZ2WXM0wjszcPUfbvqOE-CqpKDMqM hxxps://www.meetmax.com/sched/event_61861/conference_home.html?bank_access=0&;event_id=61861
yep1234
24/7/2020
08:24
DNL =3x Approvals expected during next 2 months including an Orphan Drug with FDA decision on September 29 = CHEAPEST UK Biotech a potential 500%++ GEM Diurnal Group (DNL) = MCap £38 M / Cash £15 M or enough untill early 2022 / LOTS of BIG milestones on the way = Still the MOST attractive and CHEAPEST pharma stock in UK has potential to run toward 200p very fast especially on approval of Alkindi in USA (expected in September) and Chronocort in Europe (expected in Q1 ) =STRONG BUY AGGRESSIVE a sleeping giant here .GL Market Cap £38 million Cash £15 million Price 30p Alkindi approval in Australia expected this Quarter Alkindi approval in Israel expected this Quarter FDA decision for Alkindi on September 29 EMA Decision for Chronocort expected in early Q1 2021
ih_752952
20/7/2020
16:16
They did say that, but was that an opinion or stated fact backed up with trial results? I'm not looking to argue with you, I also managed to financially benefit from the rise in SNG, but the conference call was less than impressive imo. Good luck with your investment, I assume you also hold FARN to be positing here?
diversification
20/7/2020
15:58
To be fair that isnt correct. They answered all the questions and stated for more information you will have to wait for the full report which is more technical and not entirely fit for the laymen in RNS format but the results on the basis of the questions requiring more details the results are positive which will be shown. They stipulated for interferon to be effective in the doses required for Cv19 is has to be inhaled and not injected as it would cause complications due to the concentrate required at the point needed directly in the lungs.
tidy 2
20/7/2020
15:50
I was not at all impressed with the SNG conference call, they couldn’t answer most of the questions as they didn’t have the data to hand. Let the results tell the story as if it was shown to be ineffective, WHO would it pulled the candidate from the trial in the same way it has with others. Watch this space.
diversification
20/7/2020
12:31
Doc on SNG webinar now saying interferon would not be effective injection form.
tidy 2
20/7/2020
11:50
Bloody hope so!
bwgs
20/7/2020
10:14
Can't believe how quiet this thread is, everyone must all be over at SNG...Faron's turn next?
soulected
15/7/2020
07:54
Signs of life!
raldo
22/6/2020
10:20
This is a good reading:https://link.springer.com/article/10.1007/s00134-020-06086-3
yep1234
22/6/2020
10:08
Not for severe Ards patients
cwebb07
Chat Pages: 63  62  61  60  59  58  57  56  55  54  53  52  Older
ADVFN Advertorial
Your Recent History
LSE
FARN
Faron Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201026 11:33:36